Mr. Stanislaro and Dr. Burd joined us after the session to share the highlights of the panel.

We've just finished our panel on what is going on at FDA.

I personally felt it was a great discussion.

We heard from the leading voices across academia, the investment community, market access, executives, and it was a really great discussion around a few themes.

First and foremost, the importance of advocacy and really bringing together a coalition, specifically of physicians, who feel important about an issue or a product and really can make their voices be heard, and that has a significant impact on patients receiving the therapies that they desperately need.

We also heard about stabilization at FDA, agreement on clinical trial endpoints, and the importance of getting those products reimbursed.

So this was just a great discussion across all of those different stakeholders.